Long-term, high-dose GLP-1 use leads to diminishing returns and significant muscle loss. A more effective strategy is using micro-doses in 90-day cycles, paired with nutritional coaching. This approach uses the drug as a temporary tool to eliminate carb cravings and establish lasting dietary habits.

The common misconception that GLP-1s cause muscle loss is incorrect at a cellular level. Research shows GLP-1 receptor agonists directly promote muscle protein synthesis. Muscle loss is a secondary effect of appetite suppression and inadequate protein intake, not a direct action of the drug itself.

The idea that you must consume protein within a narrow window post-exercise is a myth. Research shows that muscle protein synthesis remains elevated for over 24 hours after resistance training, making immediate protein intake unnecessary for optimizing muscle growth.

When dieting, sleep-deprived individuals lose the same amount of weight as those who are well-rested. However, 70% of the weight they lose comes from lean muscle mass, while the body retains the fat it should be losing. Sleep is critical for proper body composition changes.

Constant daily intake of some longevity molecules can have counteracting side effects. For example, taking resveratrol every other day showed a greater lifespan extension in mice than daily intake. Pulsing supplements provides a hormetic stress without constant interference.

Concerns about muscle loss from GLP-1s are often misplaced. The ratio of lean mass to fat loss is similar to that from traditional calorie restriction. This reframes the risk not as a unique side effect of the drug, but as a manageable consequence of any significant weight loss.

Fasting significantly increases natural growth hormone production. By scheduling resistance training towards the end of a fasting window—the peak of the fast—one can leverage this hormonal advantage to better retain and potentially build muscle mass.

Current GLP-1 drugs cause significant loss of metabolically crucial muscle tissue along with fat. The next breakthrough will be combining these fat-loss agents with myostatin inhibitors—biologics specifically designed to block muscle breakdown. This allows for true body recomposition, selectively targeting fat while preserving muscle mass during a caloric deficit.

The hyperglycemia from PI3K/AKT inhibitors is due to insulin resistance, not lack of insulin. Treatment must focus on insulin sensitizers (metformin, SGLT2 inhibitors). Using agents that increase insulin secretion is counterproductive as it can reactivate the PI3K cancer pathway.